Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

What is the Half-Life of Abasaglar® (insulin glargine)?

The half-life of Abasaglar is approximately 10 hours.

UK_cFAQ_BIV047_HALF_LIFE
UK_cFAQ_BIV047_HALF_LIFE
en-GB

Results of Phase 1 Clinical Studies 

3 single-site, randomized, double-blind, 2-treatment, 4-period, crossover, euglycemic clamp studies were conducted in healthy subjects to evaluate similarity in the pharmacokinetic (PK) and pharmacodynamic  of

  • Abasaglar
  • the United States (US) - approved version of Lantus, and
  • the European Union (EU) - approved version of Lantus.1

The PK parameter estimates, including half-life, were similar between between Abasaglar and Lantus (Calculated Half-Life for Abasaglar and Lantus After a Single Subcutaneous Dose).1

Calculated Half-Life for Abasaglar and Lantus After a Single Subcutaneous Dose1

Parameter

Study Drug 
(0.5 units/kg)

Geometric Mean (CV%)

n

Half-lifea, h

Abasaglar

10.0 (59)

88

US-approved Lantus

11.6 (69)

89

Abasaglar

9.95 (66)

80

EU-approved Lantus

9.76 (61)

80

Abbreviations: Abasaglar = Abasaglar® (insulin glargine) 100 units/mL; CV = coefficient of variation; US-approved/EU-approved Lantus = United States-approved/European Union-approved Lantus® (insulin glargine) 100 units/mL.

aHalf-life associated with the terminal rate constant.

References

1Linnebjerg H, Lam ECQ, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226-2233. http://dx.doi.org/10.2337/dc14-2623

Date of Last Review: July 24, 2019


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request